Businesses


Experimental COVID-19 Vaccine Safe, Generates Immune Response

Dariusz J. Nasiek, MD - Medycyna Estetyczna / Aesthetic Medicine I Physicians, Health, Beauty
July 16, 2020

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine.

The ongoing Phase 1 trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The experimental vaccine is being co-developed by researchers at NIAID and at Moderna, Inc. of Cambridge, Massachusetts.

Manufactured by Moderna, mRNA-1273 is designed to induce neutralizing antibodies directed at a portion of the coronavirus "spike" protein, which the virus uses to bind to and enter human cells. The trial was led by Lisa A. Jackson, M.D., MPH, of Kaiser Permanente Washington Health Research Institute in Seattle, where the first participant received the candidate vaccine on March 16. This interim report details the initial findings from the first 45 participants ages 18 to 55 years enrolled at the study sites in Seattle and at Emory University in Atlanta. Three groups of 15 participants received two intramuscular injections, 28 days apart, of either 25, 100 or 250 micrograms (mcg) of the investigational vaccine. All the participants received one injection; 42 received both scheduled injections.

In April, the trial was expanded to enroll adults older than age 55 years; it now has 120 participants. However, the newly published results cover the 18 to 55-year age group only.

Regarding safety, no serious adverse events were reported. More than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site. Systemic adverse events were more common following the second vaccination and in those who received the highest vaccine dose. Data on side effects and immune responses at various vaccine dosages informed the doses used or planned for use in the Phase 2 and 3 clinical trials of the investigational vaccine.

The interim analysis includes results of tests measuring levels of vaccine-induced neutralizing activity through day 43 after the second injection. Two doses of vaccine prompted high levels of neutralizing antibody activity that were above the average values seen in convalescent sera obtained from persons with confirmed COVID-19 disease.

A Phase 2 clinical trial of mRNA-1273, sponsored by Moderna, began enrollment in late May. Plans are underway to launch a Phase 3 efficacy trial in July 2020.

Regarding safety, no serious adverse events were reported. More than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site. Systemic adverse events were more common following the second vaccination and in those who received the highest vaccine dose.


Dr Dariusz J. Nasiek, MD

American Board of Anesthesiology
American Board of Pain Medicine
American Board of Interventional Pain Physicians

Expertise:

  • Author of the book “PRP – New Paradigm in Regenerative Medicine”
  • Thousands and thousands of procedures performed in the OR
  • Hundreds of legal cases represented
  • 50s interviews given and articles written 
  • Dozens of seminars conducted

Uniqueness:

  • The only practice of neurology and interventional pain dedicated 100% to helping accidents victim

Nasiek, Dariusz, MD

Aesthetic Medicine

800 River Drive
Garfield, NJ
SHOW COMPANY PHONE
tel: Click phone# to call and tell them you found their ad in Polish Pages

ARTICLES OF THIS COMPANY

Find an article

FIND A COMPANY

Add your business to our directory

Do you have a business?

  1. Register an account
  2. Add info for easy finding
  3. Get new customers
ADD A COMPANY

Copyright © 1999-2024 POLONIJNA KSIĄŻKA, a Polish Pages, Inc. company. All rights reserved. While we have made every effort to ensure the accuracy and clarity of the information presented in this catalog, we cannot be held liable for any errors or inconsistencies. Unauthorized duplication of any part of this catalog is prohibited. These materials may not be published, broadcast, rewritten, or redistributed. The publishers are not responsible for the content of published advertisements, articles and comments. Opinions contained in articles express the opinion of the authors and do not have to be in accordance with the position of the publishers. All advertisements designed by POLISH PAGES, INC. are copyrighted and can only be used in POLISH PAGES, INC. publications.